HeartSine Technologies Ltd.

Belfast, Northern Ireland and Newtown, PA– November 7, 2014 – HeartSine Technologies’ CPR Advisor™ uses revolutionary ICG technology to provide real-time visible and audible feedback to the rescuer on the quality of compressions during a Sudden Cardiac Arrest (SCA). HeartSine will showcase this patented technology which requires no additional leads or external sensors at the upcoming Medica trade fair.

Because Cardiopulmonary Resuscitation (CPR) is crucial to deliver oxygenated blood to the body’s vital organs, CPR Advisor for the HeartSine® samaritan® PAD automated external defibrillator provides accurate feedback to ensure the rescuer performs effective CPR in line with AHA and ERC guidelines.

To measure the quality of CPR compressions, CPR Advisor uses only the defibrillator electrodes -- not a third sensor -- to detect changes in patient impedance, in real time. These changes in impedance are used to measure the rate and force of compressions which correlate to a number of vital signs.

“CPR Advisor, the most innovative technology to be deployed in an AED in several years, has saved many additional lives,” says Declan O’Mahoney, CEO of HeartSine Technologies. “Competing products use a puck which is pushed on by the rescuer after being placed on the patient’s chest. Not only is this solution uncomfortable for the rescuer, it does not account for the patient’s physiology or the firmness of the surface on which the patient is lying.

CPR Advisor overcomes these drawbacks with a proven, unique solution that is now shipping on our samaritan PAD 500P product. This product is a true CPR rescue device combined with an AED.”

HeartSine will offer demonstrations of CPR Advisor and its line of samaritan PAD defibrillators at Medica on its stand C35 in Hall 9. Medica will be held at the Düsseldorf Fairgrounds in Germany on 12-15 November 2014.

About SCASudden cardiac arrest is a condition in which the heart suddenly and unexpectedly stops beating, causing blood to stop flowing to the brain and other vital organs. SCA usually causes death if it's not treated within minutes. CPR alone will not restart the heart, so the American Heart Association and ERC recommend CPR combined with early defibrillation (within three to five minutes) for the best outcome.

SCA claims more than seven million lives annually. It occurs abruptly and without warning, with 84 percent of SCA events occurring outside of the healthcare setting.

About HeartSine TechnologiesHeartSine Technologies, a world leader in personal and public access defibrillators, advances the deployment of life-saving defibrillation therapy for the treatment of Sudden Cardiac Arrest in non-traditional areas of care.

Designed for use in public areas, the company’s entire line of Automatic External Defibrillator (AED) products leverages its proprietary, clinically advanced SCOPE technology to optimize the administration of life-saving treatment.

The company’s flagship product line, the HeartSine samaritan® PAD (Public Access Defibrillator), is IP56 rated for durability and exceptional reliability to meet the unique environmental demands of public use. Its industry-leading warranty and innovative battery/electrode Pad-Pak combine to give the samaritan PAD defibrillators the lowest total cost of ownership. HeartSine is active in over 70 countries worldwide in a wide range of environments, including commercial aircraft, military and shipping facilities, manufacturing plants, offices, schools and sports clubs.

HeartSine is based in Belfast, Northern Ireland and Newtown, Pennsylvania. To learn how a HeartSine AED can save lives, please visit www.heartsine.com/ or follow HeartSine at Facebook, and Twitter.